Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.49 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.48 |
| ▸ | OTUD7B | Q6GQQ9 | 1/20 | 0.47 |
| ▸ | PLK4 | O00444 | 2/20 | 0.44 |
| ▸ | FLT3 | P36888 | 2/20 | 0.44 |
| ▸ | GHSR | Q92847 | 2/20 | 0.43 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.43 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | DRD1 | P21728 | 1/20 | 0.43 |
| ▸ | DRD5 | P21918 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | PGR | P06401 | 2/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.42 |
| ▸ | HTR7 | P34969 | 1/20 | 0.41 |
| ▸ | IP6K1 | Q92551 | 2/20 | 0.41 |
| ▸ | IP6K3 | Q96PC2 | 1/20 | 0.41 |
| ▸ | IP6K2 | Q9UHH9 | 1/20 | 0.41 |
| ▸ | MET | P08581 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29541573 | 0.92 | AKR1B1 (0.47) | AKR1B1PDE7AOTUD7BPLK4FLT3 | |
| SCHEMBL28578842 | 0.88 | PDE7A (0.55) | AKR1B1PDE7AOTUD7BPLK4PDE3B | |
| SCHEMBL29487409 | 0.88 | PDE7A (0.55) | AKR1B1PDE7AOTUD7BPLK4PDE3B | |
| SCHEMBL4263461 | 0.84 | IP6K1 (0.51) | AKR1B1PDE7AOTUD7BGHSRPDE3B | |
| SCHEMBL4263460 | 0.84 | IP6K1 (0.51) | AKR1B1PDE7AOTUD7BGHSRPDE3B | |
| SCHEMBL4717250 | 0.84 | PDE7A (0.62) | AKR1B1PDE7APDE3BPDE3APGR | |
| SCHEMBL23778428 | 0.83 | PDE7A (0.50) | AKR1B1PDE7AOTUD7BPLK4PDE3B | |
| SCHEMBL4263093 | 0.83 | PDE7A (0.50) | AKR1B1PDE7AOTUD7BPLK4PDE3B | |
| SCHEMBL23799162 | 0.82 | FLT3 (0.42) | AKR1B1PDE7AOTUD7BPLK4FLT3 | |
| SCHEMBL4273856 | 0.81 | SIGMAR1 (0.58) | DRD2HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090186889-A1 | SPIRO-SUBSTITUTED PYRROLOPYRIMIDINES | IRIE OSAMU | 2009-07-23 | — | — | US | disclosed |
| US-20090186889-A1 | SPIRO-SUBSTITUTED PYRROLOPYRIMIDINES | IRIE OSAMU | 2009-07-23 | — | — | US | disclosed |
| US-7531546-B2 | Spiro-substituted pyrrolo[2,3-D]pyrimidines as cathepsin inhibitors | NOVARTIS AG (CH) | 2009-05-12 | — | — | US | disclosed |
| US-7531546-B2 | Spiro-substituted pyrrolo[2,3-D]pyrimidines as cathepsin inhibitors | NOVARTIS AG (CH) | 2009-05-12 | — | — | US | disclosed |
| EP-1592426-B1 | 2-CYANOPYRROLOPYRIMIDINES AND PHARMACEUTICAL USES THEREOF | NOVARTIS AG (CH) | 2007-12-19 | — | — | EP | disclosed |
| WO-2004076455-A1 | SPIRO-SUBSTITUTED PYRROLOPYRIMIDINES | NOVARTIS AG (CH) | 2004-09-10 | — | — | WO | disclosed |
| WO-2004069256-A1 | 2-CYANOPYRROLOPYRIMIDINES AND PHARMACEUTICAL USES THEREOF | NOVARTIS AG (CH) | 2004-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186889-A1 | SPIRO-SUBSTITUTED PYRROLOPYRIMIDINES | CTSS, CTSK, CTSZ | AKR1B1 983/4885PDE7A 2493/4885OTUD7B 2549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.